Evidence map›Paper›PMID 40111138›Full record

ReviewBlood cancer discovery2025

Unleashing the Full Potential of Metabolic Interventions in T-ALL.

Victoria da Silva-Diz, Daniel Herranz

Abstract readReview
In one paragraph

Review in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. A dietary pan-amino acid dropout screenbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Victoria da Silva-DizRutgers Cancer Institute, Rutgers University, New Brunswick, New Jersey.ORCID 0000-0002-1508-2999
Daniel HerranzRutgers Cancer Institute, Rutgers University, New Brunswick, New Jersey.ORCID 0000-0003-1768-5969

Funding

The role of glutaminolysis as a therapeutic target in T-ALLR01CA236936 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI HERRANZ, DANIEL · 2019 to 2023
$1.8M
The role of pyruvate kinase as a therapeutic target in T-ALLR01CA285513 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Daniel Herranz · 2024 to 2026
$1.1M
NCI NIH HHS R01 CA236936NCI NIH HHS R01 CA285513
6 · The paper itself

Abstract

Drugs targeting metabolism have been effectively used in patients with T-cell acute lymphoblastic leukemia (T-ALL) for decades; still, the full therapeutic potential of targeting metabolism has not been completely exploited yet. Here, we highlight the critical need for metabolic biomarkers to advance precision medicine in T-ALL, explore the identification of novel metabolic vulnerabilities, and discuss the potential of targeted therapies and dietary interventions to optimize treatment outcomes.

Indexed as

Precursor T-Cell Lymphoblastic Leukemia-LymphomaBiomarkers, TumorHumansMolecular Targeted TherapyPrecision MedicineBiomarkers, Tumor

Identifiers

PMID40111138
PMCPMC12050939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.